BPC-157 and TB-500: What the New HHS Compounding Policy Means

What is the current announcement?

The October 28, 2026 HHS notice announces a draft enforcement-discretion policy for certain 503A compounded peptide products. It is scheduled for publication October 30, with a two-week comment period. As of this article’s October 29 update, it should not be described as a final drug approval or a confirmed pharmacy rollout.

BPC-157 and TB-500 are two of six ingredients in the framework. The central development is a proposed conditional compounding pathway while permanent rulemaking proceeds. The full announcement explainer covers that process and what to watch next.

What does the document say about BPC-157?

Appendix B of the HHS policy identifies BPC-157 acetate and describes subcutaneous, intramuscular, oral and topical dosage forms within its conditions. The precise ingredient identity matters; a product using the BPC-157 name alone does not establish that it matches the listed substance.

Oral preparations have an additional condition: the compounder is expected to keep documentation that the specific formulation achieves adequate oral bioavailability in humans. Capsule format, an absorption claim or a generic study of a different formulation does not by itself supply that formulation-specific documentation.

What does it say about TB-500?

The document identifies TB-500 acetate with the seven-amino-acid sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH. It describes subcutaneous or intramuscular injectable forms. This identity should not be conflated with full-length thymosin beta-4, whose research cannot automatically establish the effects of the shorter fragment.

That distinction is practical for anyone comparing product descriptions. The name on a sales page, the peptide sequence in the quality documentation and the compounder’s actual ingredient need to agree. The framework does not cover every preparation marketed with a related thymosin name.

Does the policy cover BPC-157 plus TB-500 blends?

The single-API condition specifies that a compounded product contains only one active pharmaceutical ingredient listed in Appendix A. A vial combining BPC-157 and TB-500 would not meet that single-ingredient condition. Inclusion of both names in the policy does not extend the same framework to a combined “Wolverine” vial.

Separate single-ingredient products and a mixed vial are different products. The document also does not establish that using separate products together improves results or is appropriate for a particular patient. Product access and evidence for a combination remain separate questions.

Can a prescription settle the question?

A prescription is one part of the framework, alongside eligible ingredients, product quality, sourcing, reporting and other requirements. It does not turn the product into an FDA-approved medicine. FDA’s compounding overview explains that these preparations do not undergo the agency’s premarket review for safety, effectiveness and quality.

When discussing access, ask for the dispensing pharmacy, exact ingredient and salt, route, and the current policy basis for the preparation. A concrete answer is more useful than a broad statement that “peptides are legal again.” Neither this announcement nor a clinic listing establishes the availability of a particular product in every state.

What does this mean for healing claims?

The announcement concerns an enforcement approach. It does not approve an injury-healing indication or establish a dosing protocol. Readers evaluating recovery claims should look for research on the actual ingredient, route and condition rather than treating the policy change as a new clinical trial result.

For a broader comparison, our BPC-157 evidence guide addresses research claims, while the six-peptide policy table explains the other covered ingredients. The regulatory question and the clinical question deserve their own answers.